Navigation Links
QLT reports initial proof of concept data for punctal plug delivery technology
Date:5/12/2008

Small study supports the potential for QLT's drug elution technology to

reduce and sustain intraocular pressure

VANCOUVER, May 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today results from a proof of concept trial conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc., of its punctal plug drug delivery technology. The results demonstrated that QLT's drug elution technology was effective in controlling intraocular pressure (IOP) and was well tolerated.

The proof of concept, open label study was initiated to determine if a sustained administration of latanoprost using the Company's punctal plug drug delivery technology could lead to a reduction in IOP over 90 days when administered using a conventional plug design. Five patients (10 eyes) with glaucoma or ocular hypertension were enrolled at a single center. The primary efficacy endpoint was measurement of IOP. At baseline, the mean IOP was 23mmHg for the 10 eyes treated. At 90 day follow-up, the mean IOP was reduced to 17mmHg for the six eyes that remained. Data from two patients were excluded due to loss of plugs. No significant adverse events were reported.

"We are very pleased to report positive results from this preliminary proof of concept trial", said Bob Butchofsky, President and Chief Executive Officer of QLT. "Although the number of patients is small, we are encouraged by the clinically meaningful reduction in IOP that was observed and sustained for approximately 90 days. We look forward to providing you with additional details from this study at our Annual General Meeting on Wednesday, May 14."

The objective of QLT's punctal plug program is to demonstrate that the Company's drug elution technology leads to a statistically significant reduction in IOP for 90 days and that its proprietary punctal plug design can be retained comfortably in a high percentage of patients during that time period. The results presented t
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Bionovo Reports First Quarter 2008 Financial Results
3. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
4. Cardium Reports on First Quarter 2008 Highlights and Financial Results
5. Novavax Reports First Quarter 2008 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
7. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
8. Pharmos Corporation Reports 2008 First Quarter Results
9. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
10. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
11. Favrille Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... MONTREAL , Feb. 1 /PRNewswire-FirstCall/ - ICBS Ltd. (OTCPK: ... TOGS(TM) 3000 bio-photonic incubation & detection systems, which the company will ... 100% accuracy in the detection of Total Coli forms and E. ... to introduce the new TOGS(TM) 3000 in the U.S, and overseas." ...
... The ... as a regulatory consultant after retiring from Eli Lilly & Co. Dr. ... human pharmaceutical products, including director of regulatory affairs and clinical research. Dr. ... submissions. , ...
... Data Demonstrating a 35% Overall Response Rate with a ... Relapsed or Relapsed/Refractory Waldenstrom,s Macroglobulinemia to be Published in ... Journal of Clinical Cancer Research , QUÉBEC CITY, ... AEZS ; TSX: AEZ) (the "Company"), a late-stage ...
Cached Biology Technology:BioSpec Global Solutions Inc, takes delivery of new TOG's 3000 Home edition for the U.S. and international markets 2Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 3Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 4Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 5
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... Interventional Radiology (SIR) will present the latest research ... bone cancer; herniated disks; peripheral arterial disease (PAD) ... its 34th Annual Scientific Meeting March 7-12� at ... Calif. Highlights of embargoed key interventional ...
... new opportunities to explore how genes influence health ... analyzing huge amounts of genetic and clinical data. ... Branch of the international Ludwig Institute for Cancer ... and the University Hospital of Lausanne have developed ...
... in Georgia and Florida with high-risk genes for type ... in a long-term study to determine how genetics and ... grant renewal from the National Institutes of Health will ... of participants from the two states in The Environmental ...
Cached Biology News:Society of Interventional Radiology hosts 34th annual scientific meeting 2Society of Interventional Radiology hosts 34th annual scientific meeting 3Society of Interventional Radiology hosts 34th annual scientific meeting 4New tool for genome-wide association studies 2Study examining role of genetics and environment in type 1 diabetes 2Study examining role of genetics and environment in type 1 diabetes 3
Useful for determination of glucose and ATP. Packaging: Package sizes are based on hexokinase units. Preparation Unit Definition: One unit will phosphorylate 1.0 mol of D -glucose per min at pH ...
ZBP-89 (S-15)...
S-100 alpha/beta chain (8B10)...
... Essentially sulfate-free, powder containing carbohydrate and ... Unit Definition: One unit will convert ... 6-phosphate to D -glucose 6-phosphate ... 25 C. Chem comp: ...
Biology Products: